Compare LQDA & IBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | IBP |
|---|---|---|
| Founded | 2004 | 1977 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.3B |
| IPO Year | 2020 | 2014 |
| Metric | LQDA | IBP |
|---|---|---|
| Price | $77.99 | $224.97 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 8 |
| Target Price | $41.00 | ★ $266.14 |
| AVG Volume (30 Days) | ★ 2.1M | 391.6K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.18% |
| EPS Growth | ★ 51.81 | 6.70 |
| EPS | 0.52 | ★ 1.29 |
| Revenue | $158,320,000.00 | ★ $2,970,800,000.00 |
| Revenue This Year | $278.87 | $1.96 |
| Revenue Next Year | $57.13 | $4.32 |
| P/E Ratio | ★ $148.19 | $174.43 |
| Revenue Growth | ★ 1031.18 | 1.00 |
| 52 Week Low | $16.51 | $193.11 |
| 52 Week High | $82.96 | $349.00 |
| Indicator | LQDA | IBP |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 51.35 |
| Support Level | $70.28 | $195.46 |
| Resistance Level | $82.96 | $229.34 |
| Average True Range (ATR) | 4.58 | 8.87 |
| MACD | -0.89 | 0.69 |
| Stochastic Oscillator | 61.43 | 52.20 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Installed Building Products Inc is an insulation installer serving the residential new construction market and are also a diversified installer of complementary building products, including waterproofing, fire-stopping and fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving, mirrors and other products throughout the United States. The company installs fiberglass insulation, spray foam insulation, and cellulose insulation. The company has three operating segments consisting of Installation, Manufacturing and Distribution operations. Majority of revenue is derived from Installation segment.